Welcome to our dedicated page for Ionq SEC filings (Ticker: IONQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IonQ, Inc. filings document a public quantum technology company with common stock, warrants and recurring capital-structure disclosures. Its 8-K reports include operating and financial results, material-event updates, registration rights agreements, unregistered equity issuances, resale prospectus supplements and acquisition-related share issuances, including the completed Skyloom Global acquisition.
IonQ proxy materials cover shareholder voting matters, board governance, executive compensation and pay-versus-performance disclosures. The company’s filing record also reflects material agreements, warrant and common-stock terms, financial reporting furnished with earnings releases, and governance matters connected to its quantum computing, networking, sensing, security and space-based data businesses.
IonQ, Inc. (IONQ) disclosure shows an insider, Inder Singh, proposes to sell 50,480 common shares through Morgan Stanley Smith Barney with an aggregate market value of $2,171,801.04. The shares were acquired by exercise of options under a registered plan (components: 2,050; 33,570; 14,860), and the proposed sale represents about 0.017% of the 296,837,796 shares outstanding. The filing lists prior sales in the past three months totaling 80,481 shares for gross proceeds of $3,117,335.44 (sales on 06/12/2025 and 08/01/2025). The notice includes the required representation that the seller is not aware of undisclosed material adverse information and references Rule 144 procedures.
IonQ, Inc. (IONQ) filed a prospectus supplement registering the resale by selling stockholders of up to 13,220,367 shares of common stock. The company will receive no proceeds from these sales. As of August 5, 2025, there were 296,841,308 shares outstanding and the last reported NYSE sale price was $42.02 per share on August 5, 2025.
The supplement discloses detailed selling stockholder positions (including institutional holders such as SK Square and USIT Holdco), escrowed shares related to the ID Quantique acquisition (including 902,160 escrowed shares), and a specified director/officer lock-up period from July 7, 2025 through September 5, 2025. The filing reiterates the companys recent operating losses of $209.1 million and $77.2 million for the six months ended June 30, 2025 and 2024, respectively, and an accumulated deficit of $892.8 million as of June 30, 2025.
IonQ, Inc. filed a prospectus supplement to its Form S-3ASR registration statement (File No. 333-285279) covering the resale by certain selling stockholders of 13,220,367 shares of common stock. A legal opinion from Paul, Weiss, Rifkind, Wharton & Garrison LLP is filed as Exhibit 5.1 and the firm's consent is included as Exhibit 23.1. The filing also includes the cover page interactive data file as Exhibit 104. The prospectus supplement and attached opinion are incorporated by reference into the registration statement to register the resale of the specified shares.
Thomas G. Kramer, Chief Financial Officer of IonQ, Inc. reported the sale of 537,880 shares of common stock on 08/06/2025 pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025. The reported weighted average sale price was $41.2804, with individual trades ranging from $40.88 to $43.00. Following these transactions, the reporting person beneficially owns 17,776 shares directly and 5 shares indirectly through a child.
The Form 4 discloses the sale activity and includes an undertaking to provide details on the number of shares sold at each price within the disclosed range upon request.
IonQ, Inc. (IONQ) – Form 4 filing dated 07/24/2025: Director Gabrielle B. Toledano received 3,696 restricted stock units (RSUs) on 07/23/2025. Each RSU converts into one share of common stock at no cost to the director.
Vesting schedule: One-third of the RSUs will vest on 02/24/2026 and on each of the next two annual anniversaries, provided Toledano continues serving on IonQ’s board.
Post-transaction holdings: Toledano now beneficially owns 10,001 common shares, held directly. No share sales or derivative transactions were reported.
The filing represents a routine equity grant meant to align the director’s incentives with shareholders; it has immaterial dilution and does not signal any change in IonQ’s operational or financial outlook.